Drug Shortages: EMA asks Companies to register a Single Point of Contact

Marketing Authorisation Holders (MAHs) can now register a central contact point, the so-called Industry Single Point of Contact (i-SPOC). This function is to inform the EMA about the supply and availability of critical medicines.

The background to this is the new Regulation (EU) 2022/123, which aims to strengthen the role of the EMA in crisis preparedness, including the monitoring and management of drug shortages. All pharmaceutical companies with a centrally or nationally authorised medicinal product in the EU are required to register a central contact point.

The i-SPOC is designed to facilitate rapid communication between EMA and regulatory authorities to identify, report and prevent or manage supply and availability problems for medicines on a list of critical medicines for a "public health emergency" or "major event". The Agency recently published the first list of critical medicines for dealing with the COVID-19 pandemic.

Registering an i-SPOC is a two-step process that can take up to 5-10 working days. The EMA has also published an IRIS User Guide and a video to support companies in the registration process.

Companies must register their i-SPOC on the EMA's IRIS online platform by 2 September 2022.

Go back


Stay informed with the GMP Newsletters from ECA

GMP Newsletter

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs.

To subscribe, please click here.